CDEK
← Mechanisms of action

MSLN

SINGLE PROTEINHomo sapiens
Preferred name: Mesothelin ChEMBL ↗

Linked proteins

Drugs acting on this target (46)

Active Pharmaceutical Ingredient Mechanism Type ▲ Approval Status API Type Mechanism of Action
amg 305Binding agentexperimentalmAbMSLN binding agent
anetumab ravtansineBinding agentexperimentalmAbMSLN binding agent
bay2287411Binding agentexperimentalSmall moleculeMSLN binding agent
bms-986484Binding agentexperimentalmAbMSLN binding agent
inezetamabBinding agentexperimentalmAbMSLN binding agent
lmb-100Binding agentexperimentalmAbMesothelin binding agent
rg-7600Binding agentexperimentalmAbMSLN binding agent
ss1(dsfv)pe38Binding agentexperimentalmAbMSLN binding agent
zw171Binding agentexperimentalmAbMSLN binding agent
crs-207Immunity, activeexperimentalVaccineMSLN immunity, active
89zr-mmot0530aImmunity, passiveexperimentalmAbMSLN immunity, passive
a2b694Immunity, passiveexperimentalCell therapyMSLN immunity, passive
abbv-428Immunity, passiveexperimentalmAbMSLN immunity, passive
amatuximabImmunity, passiveexperimentalmAbMSLN immunity, passive
anetumab ravtansineImmunity, passiveexperimentalmAbMSLN immunity, passive
autologous mesothelin-specific tcr-t cellsImmunity, passiveexperimentalCell therapyMSLN immunity, passive
bms-986148Immunity, passiveexperimentalmAbMSLN immunity, passive
cart-meso-19 t cellsImmunity, passiveexperimentalCell therapyMSLN immunity, passive
cd40 ligand expressing msln-car t cellsImmunity, passiveexperimentalCell therapyMSLN immunity, passive
cht102Immunity, passiveexperimentalCell therapyMSLN immunity, passive
hpn536Immunity, passiveexperimentalmAbMSLN immunity, passive
icasp9m28z t cell infusionsImmunity, passiveexperimentalCell therapyMSLN immunity, passive
lcar-m23Immunity, passiveexperimentalCell therapyMSLN immunity, passive
lmb-100Immunity, passiveexperimentalmAbMSLN immunity, passive
m28z1xxpd1dnr carImmunity, passiveexperimentalCell therapyMSLN immunity, passive
mesothelin car t cellsImmunity, passiveexperimentalCell therapyMSLN immunity, passive
msln star-t cellsImmunity, passiveexperimentalCell therapyMSLN immunity, passive
opb-101Immunity, passiveexperimentalCell therapyMSLN immunity, passive
pd-1 antibody expressing mesocar-t cellsImmunity, passiveexperimentalCell therapyMSLN immunity, passive
pd-1 antibody expressing mesothelin specific car-t cellsImmunity, passiveexperimentalCell therapyMSLN immunity, passive
rc88Immunity, passiveexperimentalmAbMSLN immunity, passive
rd133Immunity, passiveexperimentalCell therapyMSLN immunity, passive
rg-7600Immunity, passiveexperimentalmAbMSLN immunity, passive
ro6927005Immunity, passiveexperimentalmAbMSLN immunity, passive
synkir-110Immunity, passiveexperimentalCell therapyMSLN immunity, passive
tak-103Immunity, passiveexperimentalCell therapyMSLN immunity, passive
tc-210 t cellsImmunity, passiveexperimentalCell therapyMSLN immunity, passive
tils and car-tils targeting her2, mesothelin, psca, muc1, lewis-y, gpc3, axl, egfr, claudin18.2/6, ror1, gd1, or b7-h3Immunity, passiveexperimentalCell therapyMSLN immunity, passive
uclm802Immunity, passiveexperimentalCell therapyMSLN immunity, passive
ucmym802Immunity, passiveexperimentalCell therapyMSLN immunity, passive
αpd1/ctla4-msln-car t cellsImmunity, passiveexperimentalCell therapyMSLN immunity, passive
amatuximabInhibitorexperimentalmAbMSLN inhibitor
hy05350InhibitorexperimentalmAbMSLN inhibitor
jnj-79032421InhibitorexperimentalmAbMSLN inhibitor
sgn-mesoc2InhibitorexperimentalmAbMSLN inhibitor
ss1(dsfv)pe38InhibitorexperimentalmAbMSLN inhibitor